By: Margaret A. Hamburg, M.D. For many people, the hot summer months in the nation’s capital mean a time to depart for the beach or other less humid destinations. But one of the events I look forward to each year … Continue reading →
By Michael R. Taylor I am touring Idaho, Oregon and Washington this week with a team of FDA colleagues to learn about agriculture in this part of the country and to discuss with farmers, representatives of the food industry, agricultural … Continue reading →
The U.S. Food and Drug Administration (FDA) is reviewing reports of children who developed serious adverse effects or died after taking codeine for pain relief after tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome
El primero de agosto, 2013, La Administración de Alimentos y Medicamentos (FDA por sus siglas en inglés), informó al público que se ha asociado al acetaminofén (paracetamol) con el riesgo a reacciones poco comunes pero serias en la piel.
The U.S. Food and Drug Administration (FDA) is informing the public that acetaminophen has been associated with a risk of rare but serious skin reactions. These skin reactions, known as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), can be fatal.
